365 results
8-K
EX-99.1
ORKA
Oruka Therapeutics Inc.
13 Sep 24
Oruka Therapeutics Announces $200 Million Private Placement
4:02pm
financing for research and development, general corporate expenses, and working capital needs. The Company expects that its cash will fund its operating
8-K
ORKA
Oruka Therapeutics Inc.
5 Sep 24
Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million
5:18pm
consulting firm, where he advised biotech and pharmaceutical companies across the world on a range of research and development activities. Dr. Dambkowski
8-K
EX-99.2
ORKA
Oruka Therapeutics Inc.
5 Sep 24
Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million
5:18pm
will require significant research and development efforts, including preclinical and clinical trials and regulatory approvals to commercialization … , a one-time, non-refundable research initiation fee of $0.8 million was due to Paragon. This amount was recognized as a research and development
8-K
EX-99.4
ORKA
Oruka Therapeutics Inc.
5 Sep 24
Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million
5:18pm
if and as it:
continues its research and development and discovery-related development of its programs, ORKA-001, ORKA-002, and ORKA-003;
submits … candidates and initiates discovery-related activities and preclinical studies for those programs;
hires additional research and development and clinical
8-K
EX-99.5
ORKA
Oruka Therapeutics Inc.
5 Sep 24
Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million
5:18pm
expenses:
Research and development
6(f)
General and administrative
6(a)
6(b)
6(c)
6(d)
6(f)
Total operating expenses
Income (loss) from operations
Other … its research and development activities, (ii) sold its assets held for sale, and (iii) terminated and/or expired its operating leases. Additionally
8-K
EX-10.25
qynw rsq8ahx
5 Sep 24
Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million
5:18pm
8-K
EX-99.3
ql31m0k 5ilon
5 Sep 24
Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million
5:18pm
425
EX-99.1
z0e6r ifa1
26 Aug 24
Business combination disclosure
7:53pm
425
od3ep
26 Aug 24
Business combination disclosure
7:53pm
8-K
jhi0ifm j2x
26 Aug 24
ARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka Therapeutics
7:51pm
8-K
EX-99.1
yxpba9j1n8
26 Aug 24
ARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka Therapeutics
7:51pm
8-K
EX-99.1
9m2ze7nn38
23 Aug 24
ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka Therapeutics
4:35pm
8-K
67mo6t6qs863k4pcog9l
23 Aug 24
ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka Therapeutics
4:35pm
425
5or4l 2taf
16 Aug 24
Business combination disclosure
4:27pm
425
EX-99.1
oceiql7 3fs
16 Aug 24
Business combination disclosure
4:27pm
8-K
ztjw8d2a
16 Aug 24
ARCA biopharma Declares Special Dividend in Connection with the Proposed Merger with Oruka Therapeutics
4:25pm
8-K
EX-99.1
29f mlrs8
16 Aug 24
ARCA biopharma Declares Special Dividend in Connection with the Proposed Merger with Oruka Therapeutics
4:25pm
425
ecpm5ka4
15 Aug 24
Business combination disclosure
4:17pm
8-K
afy3gv5eyj2l9h
15 Aug 24
Entry into a Material Definitive Agreement
4:15pm
425
vz743pj85zgen4jt
9 Aug 24
Business combination disclosure
8:35am